Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Background: Published data indicated that combination use of clopidogrel and proton pump inhibitors (PPIs) may increase the incidence of major adverse cardiovascular events (MACEs). This has been a highly controversial topic for years. Design: The present study was performed to evaluate whether combination therapy of clopidogrel and PPIs is associated with increased risk of MACEs than with clopidogrel alone in patients with coronary artery disease. Methods: A systematic search of MEDLINE, EMBASE, and the Cochrane Library was conducted for studies recording the occurrence of MACEs in patients with exposure to concomitant use of clopidogrel and PPIs up to February 2015. Odds ratios (ORs) were combined using a random-effects model. Results: Patients receiving combination therapy with PPIs and clopidogrel were at significantly increased risk of MACEs (OR: 1.42; 95% confidence interval [CI]: 1.30-1.55). Adding a PPI to clopidogrel treatment was associated with a higher rate of MACE occurrence in rapid metabolizers (RMs, *1/*1) of CYP2C19 (OR: 1.42; 95% CI: 1.12-1.81), but there was no obviously increased rate (OR: 1.43; 95% CI: 0.89-2.28) in decreased metabolizers (with 1 or 2 loss-of-function allele). The increased risk of MACEs was similar in 4 classes of PPIs (omeprazole, lansoprazole, esomeprazole, and pantoprazole), but rabeprazole (OR: 1.03; 95% CI: 0.55-1.95) wasn’t. Conclusion: The combination use of clopidogrel and certain types of PPIs (omeprazole, lansoprazole, esomeprazole, pantoprazole) increases the risk of MACE in patients with coronary artery disease. Only in the RMs of CYP2C19, PPIs were associated with significantly increased MACE in patients coadministered with clopidogrel.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Optimal risk factor and lifestyle management, as well as early identification and treatment of comorbidities, is a cornerstone of treatment for T2DM.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [357]
Citations
Cites
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., Shook, T. L., Lapuerta, P., Goldsmith, M. A., Laine, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007964 · Cited by 1,240
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Smith, S. C., Allen, J., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L., Jones, D., Krumholz, H. M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.026 · Cited by 671
Trenk, D., Hochholzer, W., Fromm, M. F., Chialda, L.-E., Pahl, A., Valina, C. M., Stratz, C., Schmiebusch, P., Bestehorn, H.-P., Büttner, H. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.056 · Cited by 540
Sibbing, D., Stegherr, J., Latz, W., Koch, W., Mehilli, J., Dorrler, K., Morath, T., Schomig, A., Kastrati, A., & von Beckerath, N. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehp041 · Cited by 418
Hulot, J.-S., Collet, J.-P., Silvain, J., Pena, A., Bellemain-Appaix, A., Barthélémy, O., Cayla, G., Beygui, F., & Montalescot, G. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.071 · Cited by 383
Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450
Diaz, D., Fabrev, I., Daujat, M., Aubert, B. S., Bories, P., Michel, H., & Maurel, P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90963-2 · Cited by 308
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.010 · Cited by 239
Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors: A Cohort Study
Ray, W. A., Murray, K. T., Griffin, M. R., Chung, C. P., Smalley, W. E., Hall, K., Daugherty, J. R., Kaltenbach, L. A., & Stein, C. M. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-6-201003160-00003 · Cited by 230
Rassen, J. A., Choudhry, N. K., Avorn, J., & Schneeweiss, S. (2009) · Circulation · doi:10.1161/circulationaha.109.873497 · Cited by 220
Research works printed but not linked: 2
- Cai J, 2010, Zhongguo Ying Yong Sheng Li Xue Za Zhi, 26, 266
- Robinson M, 2001, Eur J Gastroenterol Hepatol, 13, S43
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease
Katz, P. O., Dunbar, K. B., Schnoll-Sussman, F. H., Greer, K. B., Yadlapati, R., & Spechler, S. J. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001538 · Cited by 1,038
Complications of Proton Pump Inhibitor Therapy
Vaezi, M. F., Yang, Y.-X., & Howden, C. W. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.047 · Cited by 482
The risks of long-term use of proton pump inhibitors: a critical review
Jaynes, M., & Kumar, A. B. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618809927 · Cited by 254
Luo, H., Fan, Q., Xiao, S., & Chen, K. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3358-5 · Cited by 100
Metadata
- Authors
- Niu, Q., Wang, Z., Zhang, Y., Wang, J., Zhang, P., Wang, C., Yin, X., & Hou, Y.
- Affiliations
- Shandong University (CN)
- Corresponding author
- Hou, Yinglong
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2016-08-20
- Volume
- 22
- Issue
- 2
- Pages
- 142-152
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- OpenAlex
- W2482994559
- Cited by
- 48
- References
- 39
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 10 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 2 · 2016: 1
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Cardiovascular Pharmacology and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- clopidogrel, proton pump inhibitors, major adverse cardiovascular events, coronary artery disease, CYP2C19 polymorphism, drug-drug interactions, antiplatelet therapy, omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole, rapid metabolizers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. https://app.cochat.ai/papers/10.1177/1074248416663647
- The paper
- Niu, Q., Wang, Z., Zhang, Y., Wang, J., Zhang, P., Wang, C., Yin, X., & Hou, Y. (2017). Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/1074248416663647
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.